Florence Nightingale Hospital Signs Agreement with Cerus (CERS) to Become First INTERCEPT Blood System Customer in Turkey
Cerus Corporation, a biomedical products company, today announced that Hemakim, Cerus’ distributor for Turkey, has signed an agreement with the Florence Nightingale Hospital to supply the INTERCEPT Blood System for platelets and plasma. The Florence Nightingale Hospital is a leading medical center in Turkey.
Adopting the INTERCEPT Blood System is part of the Florence Nightingale Transfusion Center’s effort to provide patients with blood products that are safe and effective – consistent with the hospital’s mission to continuously improve patient care through the use of innovative products. The Florence Nightingale Hospital strives to provide its patients and their families with the best medical treatment available, as well as with service from a clinical staff that is qualified and experienced.
Cerus shares the hospital’s dedication to patient safety and is proud to announce that its INTERCEPT system meets the Florence Nightingale Hospital’s stringent standards for healthcare technologies. Customers in 18 countries, including Turkey, have selected the INTERCEPT Blood System to protect their patients from transfusion-transmitted diseases.
The Florence Nightingale Hospital Group is based in Istanbul, Turkey, and provides patient-centered and specialized healthcare through the integration of education, research and technology with clinical care. Founded in 1989 under the body of the Turkish Cardiology Foundation, the group was established as the first cardiovascular disease hospital in that region. Currently, the Florence Nightingale Hospital Group has four general hospitals, a medical center, a teaching hospital, a clinical research center and a hi-tech hospital and is one of the largest and most respected hospitals in Europe and the Middle East.
The INTERCEPT Blood System is designed to enhance blood safety and reduce the risk of transfusion-transmitted diseases by inactivating a wide range of pathogens including viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action allows INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens like influenza, malaria and dengue.
Cerus Corporation is a biomedical products company currently focused on commercializing the INTERCEPT Blood System, which Cerus presently markets and sells for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions across the globe. For more information, visit www.cerus.com